Amlodipine/benazepril
Combination of | |
---|---|
Amlodipine | Calcium channel blocker |
Benazepril | ACE inhibitor |
Clinical data | |
Pregnancy category |
|
Legal status |
|
Routes of administration | Oral |
Identifiers | |
ATC code | None |
PubChem | CID 5746247 |
ChemSpider | 4676979 |
(verify) |
Amlodipine/benazepril, marketed in the U.S. as Lotrel by Novartis and manufactured as a generic drug by Teva and Sandoz, is an antihypertensive medication which combines a calcium channel blocker (amlodipine besilate) with an angiotensin converting enzyme inhibitor (benazepril).[1] This drug, like similar combinations, is prescribed when either agent alone is not sufficient to bring a person's blood pressure down to target range. As a combination agent, Lotrel shares the adverse reaction profile of both of its individual parts.[2][3]
See also
References
External links
|
This article is issued from Wikipedia - version of the Tuesday, January 29, 2013. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.